Edward N. Libby, MD
Position:
Associate Professor, Medical Oncology Division, University of Washington School of Medicine, Associate Member, Clinical Research Division, Fred Hutch
Research Focus:
Dr. Edward N. Libby's practice and research focus are in clinical trials for patients with multiple myeloma, Waldenström macroglobulinemia and amyloidosis.
Additional Resources:
A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
years treating myeloma: 12
Number of Myeloma Patients Treated Annually: 300
Details & contact info
825 Eastlake Avenue East Eastlake Capitol Hill
Seattle, Washington, United States, 98109
Phone: 855 557 - 0555
